StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research report report published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately, BTIG Research lowered OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.
OncoSec Medical Stock Performance
Shares of ONCS opened at $3.73 on Monday. OncoSec Medical has a 52 week low of $3.35 and a 52 week high of $34.76. The firm has a market capitalization of $6.68 million, a price-to-earnings ratio of -0.18 and a beta of 1.79. The business’s fifty day moving average price is $10.55 and its two-hundred day moving average price is $14.49.
Institutional Trading of OncoSec Medical
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.